aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Cambridge, United States, Spero Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. The company's core mission is to advance new therapies for patients with rare orphan diseases and serious bacterial infections in both hospital and community settings. Spero Therapeutics offers a technology platform that enhances the spectrum and potency of existing antibiotics, with products like SPR720, an oral antibiotic designed to treat Nontuberculous Mycobacterial Pulmonary disease.
Spero Therapeutics has garnered attention from notable investors and industry leaders, establishing itself as a key player in the infectious disease field. The company’s innovative approach has led to significant achievements, including the development of SPR720, which has the potential to be the first approved novel oral agent for its targeted condition. Spero's impact is profound, providing hope and advanced treatment options for patients battling rare and severe bacterial infections worldwide.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Antibiotics, Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Spero Therapeutics founded?
Spero Therapeutics was founded in 2013.
Where is Spero Therapeutics’s headquarters located?
Spero Therapeutics’s headquarters is located in Cambridge, CAM, GB.
When was Spero Therapeutics’s last funding round?
Spero Therapeutics’s most recent funding round was for $9M (USD) in September 2022.
How many employees does Spero Therapeutics have?
Spero Therapeutics has 35 employees as of Feb 6, 2024.
How much has Spero Therapeutics raised to-date?
As of July 05, 2023, Spero Therapeutics has raised a total of $443.6M (USD) since Sep 22, 2022.
Add Comparison
Total Raised to Date
$443.6M
USD
Last Update Sep 22, 2022
Last Deal Details
$9M
USD
Sep 22, 2022
Post Ipo Equity
Total Employees Over Time
35
As of Feb 2024
Spero Therapeutics Address
Cambridge,
Cambridgeshire
United Kingdom
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts